Arvinas, a biotech spin-out of Yale University, has raised $19.25m to fund development of a new class of drugs based on protein degradation. Of the overall fund, $15m came in the form of a series A round co-led by venture firms Canaan Partners and 5AM Ventures with participation from Connecticut Innovations and Elm Street Ventures.…
The rest of this content is only accessible to Global Venturing Subscribers.
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
